AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22851113 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2322
Study 20090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg) once daily for 6-8 weeks before H. pylori eradication (group A)
Number of subjects: 116
Study 20090337 — intervention group
Group type: COMPARATOR
Intervention: H. pylori eradication treatment followed by lansoprazole (30 mg) for 6-8 weeks (group B)
Number of subjects: 116
Study 20090337 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 116
Study 18381181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg by mouth, 3 times per day for 4 weeks)
Number of subjects: 19
Study 18381181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16387219 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 153
Study 16387219 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 153
Study 12859551 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines strategy group (ebastine, triamcinolone acetonide, and/or nedocromil sodium)
Number of subjects: 465
Study 12859551 — intervention group
Group type: COMPARATOR
Intervention: Free-choice treatment group
Number of subjects: 465
Study 12859551 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines strategy group
Number of subjects: 465
Study 10393676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/d)
Number of subjects: 211
Study 10393676 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (250 mg/d)
Number of subjects: 211
Study 9122463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 130
Study 9122463 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine methylbromide (SMB)
Number of subjects: 130
Study 2070977 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar probe
Number of subjects: 60
Study 2070977 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerosis
Number of subjects: 60
Study 6131164 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 120
Study 6131164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6131164 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Placebo
Number of subjects: 120
Study 31487902 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 20
Study 31487902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 28698133 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cooling
Number of subjects: 87
Study 26538208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg daily for 8 weeks
Number of subjects: 34
Study 26538208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24909996 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture alone (Group A)
Number of subjects: 186
Study 24909996 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin alone (Group B)
Number of subjects: 186
Study 24909996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laser acupuncture and desmopressin (Group C)
Number of subjects: 186
Study 22067280 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group received distance knowledge and distance feedback
Number of subjects: 22
Study 22067280 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (EXP) group received neither distance knowledge nor feedback
Number of subjects: 22
Study 22067280 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 22
Study 22067280 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (EXP) group
Number of subjects: 22
Study 19190916 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg hyoscine N‐butylbromide (HBB)
Number of subjects: 10
Study 19190916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 10
Study 19190916 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HBB and glucagon
Number of subjects: 10
Study 17442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve lobectomy (SL)
Number of subjects: 2984
Study 17442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery reconstruction (PAR)
Number of subjects: 2984
Study 17442581 — intervention group
Group type: COMPARATOR
Intervention: Pneumonectomy (PN)
Number of subjects: 2984
Study 15576501 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed video emphasizing the costs of not detecting cervical cancer early
Number of subjects: 441
Study 15576501 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed video emphasizing the benefits of preventing cervical cancer
Number of subjects: 441
Study 11843016 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional interventions that enhance usual care
Number of subjects: 0
Study 11843016 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support interventions
Number of subjects: 0
Study 11843016 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementation of professional services with peer support from a mother experienced in breastfeeding
Number of subjects: 0
Study 9428212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (yearly colonoscopy, liver CT, chest radiography, clinical review, and simple screening)
Number of subjects: 325
Study 9428212 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (structured clinical review and simple screening tests only)
Number of subjects: 325
Study 9428212 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly colonoscopy
Number of subjects: 325
Study 9428212 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver CT
Number of subjects: 325
Study 9428212 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 325
Study 7646261 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise Doppler echocardiography in patients with chronic cardiac failure
Number of subjects: 17
Study 7646261 — intervention group
Group type: COMPARATOR
Intervention: Control population (healthy individuals)
Number of subjects: 17
Study 7646261 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic cardiac failure
Number of subjects: 17
Study 2666139 — intervention group
Group type: EXPERIMENTAL
Intervention: SR‐Nicardipine 40 mg b.d.
Number of subjects: 36
Study 2666139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 201593 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 116
Study 201593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 201593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcoidosis patients
Number of subjects: 116
Study 201593 — intervention group
Group type: COMPARATOR
Intervention: Other diseases and normal subjects
Number of subjects: 116
Study 29548285 — intervention group
Group type: COMPARATOR
Intervention: Pf-noPQ (no primaquine)
Number of subjects: 309
Study 29548285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf-PQ1 (0.25 mg/kg primaquine)
Number of subjects: 309
Study 29548285 — intervention group
Group type: COMPARATOR
Intervention: Pv-noPQ (no primaquine)
Number of subjects: 309
Study 29548285 — intervention group
Group type: EXPERIMENTAL
Intervention: Pv-PQ14 (14 days unsupervised 3.5 mg/kg primaquine)
Number of subjects: 309
Study 27815344 — intervention group
Group type: EXPERIMENTAL
Intervention: SVG-DES (Drug-Eluting Stents)
Number of subjects: 125
Study 27815344 — intervention group
Group type: COMPARATOR
Intervention: SVG-MT (Medical Treatment)
Number of subjects: 125
Study 25691504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 0
Study 25691504 — intervention group
Group type: COMPARATOR
Intervention: Riluzole
Number of subjects: 0
Study 25691504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23588127 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric antibiotic treatment
Number of subjects: 87
Study 23588127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 20297945 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 800 mg twice a week for 26 weeks
Number of subjects: 39
Study 20297945 — intervention group
Group type: COMPARATOR
Intervention: No disulfiram (control group)
Number of subjects: 39
Study 18355302 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 0
Study 18355302 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 0
Study 18355302 — intervention group
Group type: COMPARATOR
Intervention: Gender, absolute levodopa dose, weight, disease duration, and initial motor Unified Parkinson's disease rating score
Number of subjects: 0
Study 16434338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve-mask ventilation with room air
Number of subjects: 40
Study 16434338 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation ventilator
Number of subjects: 40
Study 14517770 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients
Number of subjects: 40
Study 14517770 — intervention group
Group type: COMPARATOR
Intervention: Lean control group
Number of subjects: 40
Study 10947990 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous visuo-tactile stimulation
Number of subjects: 0
Study 10947990 — intervention group
Group type: COMPARATOR
Intervention: Tactile stimulation
Number of subjects: 0
Study 9005141 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon diathermy
Number of subjects: 50
Study 9005141 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 50
Study 1521875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 0.8 mg/kg
Number of subjects: 70
Study 1521875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6150141 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 6150141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31484571 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 646
Study 31484571 — intervention group
Group type: COMPARATOR
Intervention: Normal weight
Number of subjects: 646
Study 31484571 — intervention group
Group type: COMPARATOR
Intervention: Receiving HIV care from hospitals
Number of subjects: 646
Study 31484571 — intervention group
Group type: COMPARATOR
Intervention: No telephone contact
Number of subjects: 646
Study 29584548 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) plus Bendamustine (B); G 1,000 mg (days 1, 8, and 15, cycle 1; day 1, cycles 2 to 6) plus B 90 mg/m2/d (days 1 and 2, all cycles); G maintenance (1,000 mg every 2 months) for up to 2 years.
Number of subjects: 413
Study 29584548 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine monotherapy; B 120 mg/m2/d.
Number of subjects: 413
Study 26641379 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3-rich beetroot juice (BRJ)
Number of subjects: 13
Study 26641379 — intervention group
Group type: COMPARATOR
Intervention: NO3-depleted beetroot juice (PLA)
Number of subjects: 13
Study 24417786 — intervention group
Group type: EXPERIMENTAL
Intervention: CG100649 6 mg
Number of subjects: 30
Study 24417786 — intervention group
Group type: EXPERIMENTAL
Intervention: CG100649 6 mg + ketoconazole 400 mg
Number of subjects: 30
Study 23046564 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/day of n-3 PUFA for 8 weeks
Number of subjects: 46
Study 23046564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19890271 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 84
Study 19890271 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 84
Study 17141978 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine 500 mg (two 250-mg injections) before radiation therapy
Number of subjects: 54
Study 16215334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lance/squeeze (pain procedure)
Number of subjects: 54
Study 16215334 — intervention group
Group type: COMPARATOR
Intervention: Clustered Care (routine care giving task)
Number of subjects: 54
Study 12147537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients successfully resuscitated after cardiac arrest
Number of subjects: 61
Study 12147537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring vasopressor agents
Number of subjects: 61
Study 12147537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients analyzed for plasma endotoxin
Number of subjects: 61
Study 12147537 — intervention group
Group type: COMPARATOR
Intervention: Patients compared to healthy control subjects
Number of subjects: 61
Study 12147537 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro plasma exchange between healthy control subjects and patients
Number of subjects: 61
Study 10429602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released for hemostasis before wound closure
Number of subjects: 75
Study 10429602 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet released after wound closure
Number of subjects: 75
Study 10429602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released for hemostasis before wound closure (subgroup of cementless prostheses)
Number of subjects: 75
Study 10429602 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet released after wound closure (subgroup of cementless prostheses)
Number of subjects: 75
Study 7482105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg single oral dose
Number of subjects: 103
Study 7482105 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal suppository twice a day for 3 days
Number of subjects: 103
Study 2373576 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 30
Study 2373576 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 30
Study 2373576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg caffeine)
Number of subjects: 30
Study 7353458 — intervention group
Group type: EXPERIMENTAL
Intervention: ID glucose, 30-100 g (600-2000 ml/hr, 5% D/W)
Number of subjects: 5
Study 7353458 — intervention group
Group type: COMPARATOR
Intervention: IV normal saline (200 ml/hr and 1000 ml/hr)
Number of subjects: 5
Study 7353458 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose, 10 g (200 ml/hr, 5% D/W)
Number of subjects: 5
Study 7353458 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose, 25 g (250 ml/hr, 10% D/W)
Number of subjects: 5
Study 7353458 — intervention group
Group type: EXPERIMENTAL
Intervention: IV glucose, 100 g (1000 ml/hr, 10% D/W)
Number of subjects: 5
Study 7353458 — intervention group
Group type: COMPARATOR
Intervention: ID normal saline (1000 ml/hr)
Number of subjects: 5
Study 29484510 — intervention group
Group type: EXPERIMENTAL
Intervention: Quranic therapy sessions
Number of subjects: 121
Study 30822749 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 17
Study 30822749 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy Protein (SP)
Number of subjects: 17
Study 30822749 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 17
Study 28069062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48634
Study 25780262 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 6041
Study 25780262 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 6041
Study 22879453 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-energy supplementation (two 200-mL cans of commercial liquid formula providing additional 400 kcal of energy, 25g of protein, 9.4g of essential amino acids, 400mL of water) per day for 12 weeks
Number of subjects: 87
Study 22879453 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-energy supplementation
Number of subjects: 87
Study 22879453 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 87
Study 20952454 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 35
Study 20952454 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 35
Study 20952454 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 35
Study 19678861 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix (CM)
Number of subjects: 20
Study 19678861 — intervention group
Group type: COMPARATOR
Intervention: Free connective tissue graft (CTG)
Number of subjects: 20
Study 17100983 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg alone
Number of subjects: 11
Study 17100983 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg with naproxen 500 mg
Number of subjects: 11
Study 17100983 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg alone
Number of subjects: 11
Study 17100983 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg alone and with naproxen 500 mg
Number of subjects: 11
Study 15201942 — intervention group
Group type: COMPARATOR
Intervention: 150 mg/day IL-1ra
Number of subjects: 2900
Study 15201942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/Kg/day IL-1ra in combination with methotrexate (MTX)
Number of subjects: 2900
Study 15201942 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra (various dosages: 30, 75, and 150 mg/day)
Number of subjects: 2900
Study 15201942 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra
Number of subjects: 2900
Study 11549960 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins C and E, selenium)
Number of subjects: 16
Study 11549960 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 10176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive research articles
Number of subjects: 72
Study 10176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies developing and validating health promotion measurement tools
Number of subjects: 72
Study 10176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion theory articles
Number of subjects: 72
Study 10176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Program evaluations
Number of subjects: 72
Study 10176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 72
Study 10176374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination studies
Number of subjects: 72
Study 8266382 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for systolic hypertension
Number of subjects: 129
Study 8266382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 3307521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 41
Study 3307521 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 41
Study 28121207 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and tactile cues during bridging exercise
Number of subjects: 30
Study 28121207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional cues)
Number of subjects: 30
Study 27020278 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-Cloxacillin combination alone
Number of subjects: 14
Study 27020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-Cloxacillin combination with quinine
Number of subjects: 14
Study 27020278 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 14
Study 27020278 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics with quinine
Number of subjects: 14
Study 25236346 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months DAPT
Number of subjects: 1399
Study 25236346 — intervention group
Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 1399
Study 23733095 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact heat evoked potentials (CHEPs) at C4 and T4 dermatomes
Number of subjects: 19
Study 23733095 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact heat evoked potentials (CHEPs) at C4 and C8 dermatomes
Number of subjects: 19
Study 19918248 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with isoflavones (15 g soy protein and 100 mg isoflavones)
Number of subjects: 180
Study 18619923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing
Number of subjects: 57
Study 18619923 — intervention group
Group type: COMPARATOR
Intervention: Conventional clamping and suturing
Number of subjects: 57
Study 16627443 — intervention group
Group type: EXPERIMENTAL
Intervention: Autocapture with a pulse duration of 0.3 ms
Number of subjects: 83
Study 16627443 — intervention group
Group type: EXPERIMENTAL
Intervention: Autocapture with a pulse duration of 0.4 ms
Number of subjects: 83
Study 16627443 — intervention group
Group type: COMPARATOR
Intervention: Standard output programming (3.5 V, 0.4 ms)
Number of subjects: 83
Study 16627443 — intervention group
Group type: COMPARATOR
Intervention: Conventional low output programming (2.5 V, 0.4 ms)
Number of subjects: 83
Study 16627443 — intervention group
Group type: EXPERIMENTAL
Intervention: Autocapture function
Number of subjects: 83
Study 12954308 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof intraocular lens (MA30BA or MA60BM, Alcon)
Number of subjects: 107
Study 12954308 — intervention group
Group type: COMPARATOR
Intervention: Plate-haptic silicone intraocular lens (AA4203VF, Staar)
Number of subjects: 107
Study 12954308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 12536506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired activated protein C resistance (APCR)
Number of subjects: 30
Study 12536506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LA) positive
Number of subjects: 30
Study 12536506 — intervention group
Group type: COMPARATOR
Intervention: APCR negative
Number of subjects: 30
Study 12536506 — intervention group
Group type: COMPARATOR
Intervention: LA negative
Number of subjects: 30
Study 9403579 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (estradiol valerate, 2 mg daily, n=7)
Number of subjects: 12
Study 9403579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 12